Home
Live Updates
Travere Therapeutics Reports First Quarter 2024 Financial Results : comparemela.com
Travere Therapeutics Reports First Quarter 2024 Financial Results
FDA grants Priority Review for sNDA to convert FILSPARI® from accelerated approval to full approval for the treatment of IgAN in the U.S.; PDUFA target action date of September 5, 2024 Received 511...
Related Keywords
Japan ,
United States ,
Norway ,
Iceland ,
Liechtenstein ,
Japanese ,
American ,
Renalys Pharma ,
Deric Dube ,
Drug Administration ,
Program Updates ,
National Symposium ,
American Nephrology Nurses Association ,
European Commission ,
Exchange Commission ,
Ligand Pharmaceuticals ,
Devices Agency ,
Travere Therapeutics Inc ,
Society For Inherited Metabolic Disorders ,
Nasdaq ,
Renalys Pharma Inc ,
European Union ,
Genetic Metabolic Dieticians International ,
World Congress ,
Priority Review Of The Company ,
Priority Review ,
Continuing Operations ,
Quarter Ended March ,
New Drug Application ,
Medical Devices Agency ,
Investigational New Drug ,
Kidney Disease Improving Global Outcomes ,
Clinical Practice Guideline ,
Focal Segmental Glomerulosclerosis ,
Inherited Metabolic Disorders ,
Travere Therapeutics ,
Important Safety Information ,
Endothelin Receptor Antagonists ,
Upper Limit ,
Fetal Toxicity ,
Full Prescribing Information ,
Private Securities Litigation Reform Act ,
Months Ended March ,
Markets ,
comparemela.com © 2020. All Rights Reserved.